Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical vs Subcutaneous Secukinumab in Hidradenitis Suppurativa
NCT07261072Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in hidradenitis suppurativa (HS), sponsored by Peking Union Medical College. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07261072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07261072.